Objectives: There is controversy regarding the benefits of N-acetylcysteine in acute kidney injury. This study was to compare three commonly used regimens and explore which regimen is best for the protection of acute kidney injury.
A cute kidney injury (AKI) is common and is associated with increased hospital mortality (1) (2) (3) . As many as 67% of critically ill patients have evidence of AKI by RIFLE (Risk Injury Failure Loss ESKD [end-stage kidney disease]) criteria (4 -6) . The cause of AKI in critically ill patients is often multifactorial (3) . Between 45% and 70% of all AKI is associated with sepsis (2, 6 -8) . Nephrotoxic drugs and contrast materials are implicated in 19% to 25% (2, 9) . Drugs excreted by the kidney may exert direct toxic effects to the renal tubules or induce inflammation in the renal interstitium in acute interstitial nephritis (10) .
Given the apparent effect of AKI on mortality, it is important to prevent or hasten the resolution of even the mildest forms of AKI. However, there are very few interventions that have been shown to consistently prevent AKI. Measures such as ensuring adequate hydration, maintenance of adequate circulating blood volume and mean arterial pressure, and avoidance of nephrotoxins are still the mainstay of prevention (11) . Until now, there is no effective pharmacologic strategy that can be used to prevent or to treat AKI.
Several studies support the involvement of reactive oxygen species in the development of various forms of AKI (12) . Neutralization of these metabolites by natural antioxidants could reduce toxicity. N-acetylcysteine (NAC) has been successfully used in various animal models of AKI (13) (14) (15) . NAC, the acetylated variant of amino acid cysteine, is an excellent source of sulfhydryl groups and increases glutathione synthesis, promoting detoxification and acting directly as a free radical scavenger. Among the available pharmacologic options, NAC has perhaps the strongest evidence in prevention of AKI (11) .
However, NAC could also cause harm because it can be pro-oxidative in certain settings (16, 17) . In vitro, NAC can increase hydroxyl radical generation when free iron is available by reducing ferric iron to its catalytic, active Fe 2ϩ form. Indeed, although some clinical trials demonstrated protective effects of NAC, others have not (18, 19) and differences in treatment protocols could underlie the disparities in results obtained (20) . Indeed, many centers do not use NAC and further studies are necessary to demonstrate whether there may be any benefits of therapy in various settings. It is possible that NAC may be beneficial in selected groups of patients, doses (19) , or specific prescribed regimens, although it is ineffective or even harmful in others (20) .
We hypothesized that different treatment regimens for NAC would be associated with different efficacy in limiting AKI after folic acid (FA) exposure. Therefore, this study compared the three commonly used regimens (pretreatment, posttreatment, and combined pre-and posttreatment) and explored which regimen is best for the protection of AKI.
MATERIALS AND METHODS
Animals. Outbred male CD-1 mice (Charles River, 6 -8 wks old, weight 28 -32 g) were housed in an air-conditioned room with 12-hr light-dark cycles, constant temperature (21 Ϯ 2°C), relative humidity (60% to 65%), and free access to water and food. All procedures were performed with the approval of the University of Pittsburgh Animal Care and Use Committee and in accordance with National Institutes of Health guidelines.
Experimental Models. This study consists of two experimental models based on the severity of AKI. In the first model (severe), mice were randomly assigned to four groups. AKI was induced with 350 mg/kg (Sigma Aldrich, St Louis, MO) of FA intraperitoneal injection. Mice in the pretreatment group were treated with subcutaneous injection of 300 mg/kg of NAC (Sigma Aldrich) at 24 and 6 hrs before the FA injection (n ϭ 15). Mice in the posttreatment group were treated with subcutaneous injection of 300 mg/kg of NAC at 6 and 24 hrs after FA injection (n ϭ 12). Mice in the pre-ϩ posttreatment group were treated with 300 mg/kg NAC at 24 and 6 hrs before the FA injection and at 6, 24, and 48 hrs after the FA injection (n ϭ 12). The dose and timing of NAC administration were based on and modified from studies showing benefit with NAC (13) (14) (15) . In a fourth group, the same amounts of normal saline were given subcutaneously at the same time points as the pre-ϩ posttreatment group (n ϭ 15). In the second model (mild), AKI was induced with 250 mg/kg of FA intraperitoneal injection. The same groups (n ϭ 12 each) with the same interventions as the severe model were carried out. Finally, in a third experiment, the same dose of NAC as the pre-ϩ posttreatment group was administered to 14 mice without FA injection to evaluate the direct toxicity of NAC (six were euthanized for tissue oxidative analysis as controls after all NAC doses were given).
From all animals, we drew blood (0.1 mL per time) from the greater saphenous vein 4 days before FA injection as baseline and on days 1, 2, 3, and 7 after FA injection. Plasma was collected after centrifugation at 1500 g for 10 mins. All samples were stored at Ϫ80°C until assay. Survival time was assessed up to 7 days.
To evaluate kidney histology, another experiment consisting of 24 mice with the same interventions (pretreatment, posttreatment, pre-ϩ posttreatment and placebo, n ϭ 6 each) was carried out. These mice were euthanized on day 2 after FA injection for histologic observation and tissue oxidative analysis.
Assessment of Renal Function. Plasma concentrations of creatinine (Cr) and cystatin C were measured to evaluate glomerular function. Plasma Cr was measured with a creatinine enzymatic assay kit (BioVision Technologies, Mountain View, CA). Cystatin C was measured with an enzyme-linked immunosorbent assay kit (BioVendor, Candler, NC). The severity of AKI was assessed using Risk, Injury, Failure, Loss, End-stage kidney disease (RIFLE) criteria based on the change in plasma Cr. The criteria are: R, Risk (Cr increases Ͼ50%); I, Injury (Cr increases Ͼ100%); F, Failure (Cr increases Ͼ200%).
Analysis of Oxidative Injury. Reduced glutathione (GSH) was determined by the Glutathione Colorimetric Detection Kit (BioVision, Technologies). Proteins were first removed from plasma samples by using 5-sulfosalicylic acid. GSH and 5,5Ј-dithiobis (2nitrobenzoic acid) react to generate 2-nitro-5-thiobenzoic acid, which has a yellow color. The GSH concentrations from blood and kidney tissue were determined by measuring absorbance at 405 nm.
Malondialdehyde contents from kidney tissue were measured with the thiobarbituric acid reactive substances assay kit (Cayman Chemical Company, Ann Arbor, MI). The malondialdehyde-thiobarbituric acid adduct formed by the reaction of malondialdehyde and thiobarbituric acid under high temperature (90 -100°C) and acidic conditions is measured colorimetrically at 530 -540 nm.
Evaluation of Kidney Histology. Kidney sections were fixed in 10% neutral buffered formalin, dehydrated in graded anhydrous absolute ethanol, and embedded in paraffin. Histologic sections (5 m) of kidney were stained with hematoxylin, eosin, and periodic acid Schiff. We considered the morphologic changes indicating acute tubular necrosis as the loss of membrane and nuclear integrity, the loss of brush border, the vacuolization of tubular epithelial cells, and the presence of intratubular debris.
Statistical Analyses. All numeric data with normal distribution were expressed as mean Ϯ SD. Mean differences among the four groups and among different time points were analyzed by analysis of variance for repeated measures. When significant differences among groups and time points were found, pairwise comparisons were used with Bonferroni adjustment. The primary tests of interest are the comparisons between NAC-treated groups and the placebo-treated group at each time point. Numeric data without normal distribution (data for renal oxidative parameters, survivaldays) were expressed as median (ranges) and compared with Kruskal-Wallis test. Categorical data (RIFLE criterion) were expressed as percentage and were compared with chisquare tests. Survival time was assessed by Kaplan-Meier method (log rank test) and overall survival in each group was compared using Fisher's exact test. All analyses were conducted using the SPSS statistical software package (SPSS for Windows, Chicago, IL). p values Ͻ .05 were considered to be statistically significant.
RESULTS

NAC Pretreatment Improved Survival, Whereas Posttreatment Worsened Survival.
Survival was evaluated for 7 days. Pretreatment with NAC resulted in significantly better survival compared with placebo-treated animals (log rank test, p ϭ .03, Fig. 1 ) with a greater 7-day survival rate (73.33% vs. 46.67%, p ϭ .04) and a longer median survival time (6.13, vs. 4.63 days, p ϭ .03, Fig. 1A ). In contrast, mice treated with posttreatment did not show any difference in survival and mice treated before and after FA actually exhibited significantly lower survival rates (16.67% vs. 46.67%, p ϭ .01) compared with placebo. There were no deaths or other apparent adverse effects among animals receiving 5 days of NAC in the absence of FA.
NAC Pretreatment Alleviated FA-Induced AKI, Whereas Posttreatment Worsened AKI. In placebo-treated animals exposed to FA, plasma Cr increased early (1 day) after exposure and reached a peak at day 2 and then recovered to baseline by day 7 (Fig. 2A ). The pretreatment group exhibited significant protection (0.82 vs. 1.19 mg/dL on day 2, p ϭ .01) compared with placebo, whereas the posttreatment group did not show this effect. Pre-ϩ posttreatment with NAC significantly worsened the Cr (1.28 vs. 0.72 mg/dL on day 3, p ϭ .01). Cystatin C changes were similar to those of Cr. NAC pretreatment significantly attenuated the increased cystatin C on days 1, 3, and 7 (p Ͻ .05, Fig. 2B ).
NAC Pretreatment Mitigated the FA-Induced Oxidative Injury, Whereas Posttreatment Did Not. Plasma GSH decreased sharply at day 1 after FA injection. The GSH in pretreatment mice began to recover and increase from day 2 compared with placebo (11.5 vs. 8.1 g/ mL, p ϭ .04, Fig. 3A ). However, the GSH in both posttreatment groups continued to decrease and was even lower than that in the placebo group on day 3 (7.3 vs. 9.5 g/mL, Fig. 3A ). Renal GSH contents decreased and renal malondialdehyde contents increased at day 2 after FA injection compared with the normal control. NAC pretreatment increased renal GSH and decreased malondialdehyde contents ( Fig. 3B-C) , whereas both pre-ϩ posttreatment and posttreatment had the trend to worsen oxidative injury.
NAC Pretreatment Improved FA-Induced Kidney Histology, Whereas Posttreatment Did Not. Figure 4 shows the kidney histology under light microscopy. Renal tubules in all mice showed loss of brush border, vacuolation of cells, and acute tubular necrosis 2 days after FA injection. These pathologic changes were attenuated in the pretreatment group ( Fig. 4A ) but were actually worse in the posttreatment group (Fig. 4C) .
NAC Pretreatment Improved Survival, Which Was Related to the Reduced Oxidative Injury and Subsequently Reduced AKI Severity. The plasma GSH contents at day 2 of FA injection categorized as AKI RIFLE-R from all groups were significantly higher than those categorized as RIFLE-I and RIFLE-F (11.4 vs. 8.8, p ϭ .01; 11.4 vs. 8.0 g/mL, p ϭ .01; respectively, Fig. 5A ). On the other hand, there was a lower percentage of RIFLE-F AKI in the pretreatment group (32%) compared with other groups (67% to 72%) ( Fig.  5C ). Figure 5B shows mortality by RIFLE strata. Mortality increased from 17% (two of 12) with RIFLE-R to 44% (eight of 18) with RIFLE-I to 85% (17 of 20) with RIFLE-F.
Both NAC Pretreatment and Posttreatment Neither Improved Nor Worsened Renal Function in the Milder AKI Model. Finally, to explore whether the NAC-induced paradoxic oxidative effects seen in our severe AKI model are related to the severity of injury, we also studied the effect of NAC in a mild AKI model. A lower dose of FA (250 mg/kg) induced mild temporary AKI. In this model, all of the various NAC regimens demonstrated trends to reduced AKI, but the differences were not statistically significant ( Fig. 6 ). Neither pre-ϩ posttreatment nor posttreatment showed harm in this model. 
DISCUSSION
Our results demonstrate that NAC pretreatment is effective in reducing the severity of AKI as well as increasing survival time in experimental nephrotoxicity, whereas NAC posttreatment was not effective and even worsened AKI. The protective effect of NAC was apparently related to the replenishing depleted GSH, whereas the harmful effect might be induced by NAC's pro-oxidative actions in the setting of injury and inflammation (16, 17) . Our results also show that oxi-dative injury plays an important role in FA-induced AKI but that NAC is only effective for prevention, not treatment. This study has thus confirmed and extended the observation that NAC is only effective in preventing AKI induced by nephrotoxic substances, but worsens AKI when given for treatment, at least under some conditions (16, 17, 21) . Although our results cannot be directly translated into clinical practice, they do raise important cautionary notes regarding the use of NAC in the clinical setting.
In this study, we administered intraperitoneal FA to induce AKI. FA is a water-soluble vitamin that precipitates in the acidic urine within the tubules. In high concentration, this may result in epithelial hypoxia, renal tubular necrosis, renal failure, and even death after several hours or days (22) . In the first few days after injury, epithelial proliferation leads to epithelial regeneration of some tubules and gradually leads to renal recovery (22) (23) (24) . This model may mimic clinically relevant AKI secondary to various toxins, medications, or contrast media. However, we also chose FA because it has no systemic effects that would confound assessment of oxidative stress. Our results may not be relevant to sepsis-induced AKI or AKI caused by any number of other insults (e.g., ischemia/reperfusion). A dose of 250 mg/kg of FA has been used for chronic kidney injury (22) or the first hit model together with the second hit (23, 24) . This dose induces only mild kidney injury (Fig. 6 ). Using this lower dose, we could not find any significant changes even with high-dose NAC treatment. Thus, we chose a higher dose of FA (350 mg/kg) to induce much more severe AKI and observed significant changes with NAC treatment.
Subcutaneous injection of 300 mg/kg of NAC was used in this study, which is greater than that commonly used in humans. However, the dose was based on and modified from studies showing benefit with NAC (13) (14) (15) . A study by Di Giorno demonstrated a dose-dependent (40 -300 mg/kg peritoneal injection) renal protection. A dose of 300 mg/kg NAC showed better renal function than other doses (14) . The ideal concentration for NAC to induce anti-inflammatory and antioxidative effects is 2-10 mM (25, 26) . In a human volunteer study, 200 mg NAC intravenous injection only led to a peak NAC plasma concentration 0.07 mM (27) . However, a study by Sprong et al (17) calculated the intraperitoneal injection at concentrations of 200 -1000 mg/kg of NAC in rats led to peak NAC plasma concentrations of approximately 3-15 mM. In humans, the dose of intravenous NAC used for prevention of contrast-induced AKI has been as high as 1200 mg every 12 hrs for 48 hrs (total dose 6000 mg) (28) . This dose would be expected to achieve plasma concentrations of approximately 4 -6 mM. Thus, our dosing strategy is in line with the high-dose regimens being used in some studies of contrast-induced AKI. We administered NAC subcutaneously rather than intraperitoneally to avoid the possible formation of complexes with FA, because subcutaneous administration has also been reported to induce protective effects in animals (29) and humans (30) .
Our results are compatible with our recent findings in patients undergoing liver transplant (31) , in which we found that pre-ϩ posttreatment with NAC was not effective in reducing the incidence of AKI. Importantly, we also found that NAC was effective in increasing GSH in only approximately 50% of patients and that and fewer patients developed AKI when GSH levels were increased. Our results in this study were similar in that NAC appeared to be protective when GSH levels were increased.
Other groups have also found mixed results with NAC for preventing AKI. Most clinical studies have been done in the setting of contrast nephropathy. Data from meta-analyses are also conflicting and show significant heterogeneity be- tween studies. Seven of 13 recently published meta-analyses concluded that NAC is beneficial for preventing contrastinduced nephropathy. Differences in study design, patient populations, treatment protocols, and primary outcomes may explain this heterogeneity. The protective effects of NAC may be related to timing, dosing, and the severity of AKI (18 -20, 31, 32) . Furthermore, a recent large retrospective cohort study of 7977 patients with contrast exposures performed at the Mayo Clinic suggested that there was a trend toward decreased incidence of nephropathy in cases in which administration of NAC was performed on 2 consecutive days (1 day before and the day of contrast administration). In those cases in which NAC was administered in other regimens, there was a trend toward increased incidence of renal injury (20) . Although these results are only trends, the signal is quite consistent with our results.
If NAC causes increased injury to the kidney when given after a nephrotoxic insult, the mechanism is unclear. In our study, GSH levels in posttreatment did not improve after being reduced by FA. This observation could suggest further oxidation of GSH by oxidative stress induced by NAC as well as by FA. This effect of NAC is supported by the considerable literature reporting that low-molecularweight thiols are pro-oxidants as well as antioxidants (33) . Pro-oxidant activity is the result of transition metal-dependent auto-oxidation yielding O Ϫ 2⅐, H 2 O 2 , and the reduced form of the transition metal, which may behave as a catalyst in free radical reactions. Under normal physiological circumstances, metals are bound to circulating proteins and are rendered redox-inactive (33, 34) . However, levels of free metal ions, including iron, may be elevated in a variety of clinical conditions (including inflammation, sepsis, and cardiopulmonary bypass) and become redoxactive (35, 36) . Because this autooxidation only occurs during stress, it could explain why posttreatment worsened AKI. A study by Molnar et al (37) suggested that the initiation of NAC treatment Ͼ24 hrs after hospital admission may potentially be harmful in critical illness. Furthermore, the more severe the AKI is, the higher levels of the free iron. It may explain why NAC was not effective in severe AKI in previous studies (18, 21) . In severe sepsis, NAC treatment even aggravated organ failure (38) . Data from our mild AKI model showed both post-and pre-ϩ posttreatment with NAC neither worsened AKI nor changed oxida-tive injury. This suggested that severity of injury played an important role in the progression of auto-oxidation. We also speculate that a relatively high NAC dose can actually worsen oxidative stress. Before day 1, both the group with pretreatment and the group with pre-ϩ posttreatment received the same intervention. The group with pre-ϩ posttreatment received three more doses of NAC from day 1 to day 3. These additional doses may have caused harm. A study by Laisalmi-Kokki (16) showed the potentially detrimental effects of NAC on renal function in knee arthroplasty when a loading dose of NAC was infused in a short time. In a rodent endotoxin model, low doses of NAC protected against oxidative stress by directly scavenging oxygen radicals. On the contrary, higher doses decreased animal survival and increased oxidative stress by auto-oxidation of NAC sulfhydryl groups (17) . The concentration-dependent reduction of ferricytochrome-c by NAC was also reported in this study. In a human model of acute muscle injury induced by eccentric exercise, a study by Childs et al (39) showed that a combination of vitamin C and NAC possesses pro-oxidative properties. In our study, this increased dose could not be attributed to a direct toxic effect of NAC itself, because there were no deaths among animals receiving the 5 days of NAC in mice without FA. However, this high cumulative dose of NAC might have resulted in a paradoxically higher oxidative stress in animals treated with FA. Once again, it indicated that this dosedependent auto-oxidation only occurred in severe injury.
There are limitations to our study. First, we did not measure plasma NAC or its metabolites, so we were not able to evaluate the potential correlations of NAC concentration on AKI. Second, pretreatment with NAC did not prevent AKI but rather reduced its severity. However, AKI was sustained for several days after the intervention and there appeared to be significant differences between groups in terms of RIFLE class, Cr, and cystatin C over time. Indeed, it has been suggested that cystatin C may be a more accurate measure of renal function, particularly in the presence of NAC (40, 41) . Finally, FA is an unusual cause of AKI in humans. However, FA bears similarities to other nephrotoxins and has the added benefit of having no confounding systemic effects. Fourth, intravenous or intraperitoneal administration of NAC is presumably su- Figure 6 . Effects of N-acetylcysteine on renal function and oxidative injury in mild acute kidney injury A, Effects of N-acetylcysteine on plasma creatinine (mean Ϯ SD, mg/dL, n ϭ 12). B, Effects of N-acetylcysteine on plasma glutathione (GSH) (mean Ϯ SD, g/dL, n ϭ 12). perior to oral use, because the former has a rapid onset of effect, complete bioavailability, and higher peak serum NAC levels. We administered NAC subcutaneously rather than intraperitoneally to avoid the possible formation of complexes with FA.
In summary, our data indicate that the renal protective effects of NAC in the setting of nephrotoxic (FA-induced) AKI are limited to pretreatment. When given after onset of AKI and in high concentrations, NAC did not decrease oxidative stress and even worsened FA toxicity. Further studies are needed to determine the exact mechanism of this effect and whether it is applicable to humans with contrast-induced and other forms of AKI. Nevertheless, given the controversial nature of the existing evidence for NAC, evidence of potential harm, seen in this study, should prompt a re-evaluation of NAC, particularly when used a posttreatment regimen.
